Drug Database
FA

Factor VIIIa (LongAte)

✓ Approved

PolyTherics Limited · F8 · Recombinant Proteins

What is Factor VIIIa?

Factor VIIIa is a recombinant proteins developed by PolyTherics Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesLongAte
CompanyPolyTherics Limited
Drug ClassRecombinant Proteins, Cell-based Therapies
Molecular TargetF8
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, PolyTherics Limited

Mechanism of Action

Molecular Targets

Factor VIIIa acts on 1 molecular target:

F8coagulation factor VIII (AHF, FVIII)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

Factor VIIIa is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedInternational journal of pharmaceutics: X2026-08-30

Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.

Ouyang Ting T, Chen Yumo Y, Jia Yiying Y, Li Jiarui J et al.

Budesonide (BUD) enema therapy for ulcerative colitis (UC) is limited by poor solubility, inadequate bio-adhesion, and rapid clearance due to intestinal peristalsis. To address the limitations of conventional budesonide enemas, we designed a water-triggered in situ phase-transition phospholipid formulation (termed PG oil). This system comprises soybean phosphatidylcholine (PC-98), glyceryl dioleate (GDO), propylene glycol, and anhydrous ethanol, and achieves markedly enhanced BUD solubilization (35 mg/mL), in contrast to its negligible aqueous solubility (0.021 mg/mL). Upon contact with colonic fluid, PG oil rapidly underwent sol-gel transition, forming a bio-adhesive lamellar liquid crystalline gel that serves as both a physical mucosal barrier and a sustained-release drug depot. In a dextran sulfate sodium (DSS)-induced colitis mouse model, rectal administration of BUD-PG oil (0.3 mg/kg) significantly outperformed free BUD suspension, as evidenced by restored body weight, reduced disease activity index, normalized colon length, and decreased spleen index. Immunohistochemistry revealed marked suppression of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, MCP-1) in colonic tissue. Histological analysis demonstrated that BUD-PG promoted favorable mucosal repair characterized by reduced collagen deposition (Masson's trichrome: from 48.5% to 16.7%) while restoring gut barrier integrity through replenishment of goblet cells and upregulation of tight junction proteins (ZO-1, Occludin-1, Claudin-5, β-catenin). Collectively, this water-responsive in situ gelling phospholipid oil platform addresses critical limitations of conventional BUD enemas by combining sustained local drug delivery with physical mucosal protection, offering a promising therapeutic strategy for comprehensive mucosal healing in UC.

PMID 42668512
Read full article →
PubMedEuropean heart journal2026-08-30

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes.

Wang Yifan Y, Danchin Nicolas N, Simon Tabassome T, Zeller Marianne M et al.

Cardiogenic shock (CS) is the most dreadful complication of acute coronary syndromes (ACS). Endothelial dysfunction and vascular leakage are hallmarks of CS pathophysiology; however, biomarkers reflecting these early processes are lacking. The adrenomedullin (ADM) system-the inactive precursor glycine-extended ADM (ADM-Gly), the activating enzyme peptidylglycine α-amidating monooxygenase (PAM), and biologically active ADM (bio-ADM)-modulates vascular tone and permeability. This study investigated associations of ADM system components with CS and 1-year mortality risk after ACS. ADM-Gly, PAM, and bio-ADM were assessed in 4098 (Switzerland; SPUM-ACS) and 824 (France; FAST-MI) ACS patients without CS on admission. The primary endpoint was in-hospital CS; the secondary endpoint was 1-year mortality. Biomarker-outcome associations were analysed using multivariable-adjusted regression models, and the incremental predictive value beyond established risk scores was quantified. Higher ADM-Gly and bio-ADM, but not PAM, were associated with systemic inflammation and haemodynamic compromise. ADM-Gly and bio-ADM independently predicted CS risk in Switzerland (adjusted odds ratio [aOR] per log2 increase, 1.44, 95% confidence interval [CI] 1.22-1.71, P < .001 and aOR 1.37, 95% CI 1.10-1.70, P = .004) and France (adjusted risk ratio [RR] per log2 increase, 1.82, 95% CI 1.34-2.48, P < .001 and aRR 1.55, 95% CI 1.15-2.10, P = .004), and were associated with 1-year mortality risk (adjusted hazard ratio [aHR] per log2 increase, 1.33, 95% CI 1.09-1.61, P = .005 and aHR 1.46, 95% CI 1.15-1.86, P = .002). Addition of ADM-Gly and bio-ADM to the ORBI risk score improved its discrimination (Δ area under the receiver operating characteristic curve 0.02), reclassification (net reclassification improvement 0.229), and model fit (Δ Akaike information criterion -26.9), with consistent results in external validation. ADM-Gly and bio-ADM, but not PAM, independently predict in-hospital CS and 1-year mortality risk in initially stable patients with ACS and improve early risk stratification.

PMID 42668424
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

Regulating Cells Fate and Function to Facilitate Bone Regeneration via Designing Programmable Bio-Interactive Materials.

Fan Qingrui Q, Cao Fuming F, Mao Junqiang J, Yin Pengbin P et al.

Achieving efficient bone repair necessitates a thorough understanding of the physiological activities of native bone tissue, enabling selection and design of appropriate materials. To date, artificial scaffolds have been developed from inert materials to bioactive materials and demonstrate the capabilities to promote bone repair. However, the complex physiological changes that occur during bone repair pose significant challenges to their practical clinical applications. In this Review, we summarize the studies of bone biology and the evolution of materials design in the context of bone-tissue engineering applications. Specifically, we emphasize the role of biomaterials from a materials science perspective in regulating cell fates. Furthermore, we introduce the concept of programmable bio-interactive materials as a potential solution for bone regeneration. These materials possess the ability to dynamically and precisely interact with biological systems, guiding the bone-tissue regeneration process. Additionally, we discuss the unmet needs and current challenges faced in the development of bio-interactive materials for bone-tissue regeneration. By highlighting emerging strategies in the field, we aim to shed light on future directions for research and development in this exciting area of study.

PMID 42669154
Read full article →
PubMedFood chemistry: X2026-08-30

Effect of solid-state fermentation on the release and antioxidant activity of soluble polyphenols from wheat bran.

Tian Xiaomin X, Guo Yuqiu Y, Sun Linlin L, Chen Lirong L et al.

Using wheat bran as substrate, four solid-state fermentation methods were compared for soluble polyphenol release. The effect of Bio-enzymatic synergy (BES) is the most significant, producing 4.85 mg GAE/g of total phenolic substances, which is 45.77% higher than the control group (CK). LC-MS analysis revealed that ferulamide and 2,4,6-trihydroxybenzoic acid predominated in positive ion mode, while salicylic acid dominated in negative mode. Notably, salicylic acid was found almost exclusively in ester-bound and glycoside-bound fractions (>88%), indicating its release requires cleavage of covalent linkages to cell wall components. The release of salicylic acid results from the synergistic action of Bio-enzymatic synergy and alkaline hydrolysis. Both in vitro and in vivo assays confirmed that BES-released polyphenols enhanced antioxidant activity, reducing ROS and MDA levels while increasing GSH-Px activity and extending C. elegans lifespan. These findings provide a mechanistic basis for developing targeted fermentation-enzymatic processes to produce functional wheat bran extracts.

PMID 42668496
Read full article →
PubMediScience2026-08-30

Uridine and pyruvate supplementation is associated with Th1 polarization during mitotoxic antibiotic therapy.

De Santis Stefania S, Rutigliano Monica M, Simone Federica F, Larocca Letizia L et al.

Antibiotics with off-target mitochondrial toxicity can impair host immunity, yet their impact on human adaptive immunity in vivo remains unclear. Because T cell activation and differentiation depend on mitochondrial metabolism, antibiotic-induced mitochondrial stress may alter T helper cell function. We investigated whether uridine and pyruvate (UP) supplementation modulates immune responses in patients receiving mitotoxic antibiotics. In a pilot observational study, 67 patients undergoing prophylactic antibiotic therapy received either antibiotics alone or antibiotics plus daily UP supplementation. Antibiotic exposure increased circulating growth differentiation factor-15 (GDF15), indicating mitochondrial stress, and altered T cell response. UP supplementation was associated with immune features consistent with preserved inflammatory competence, including a trend toward Th1 polarization. These findings suggest that mitotoxic antibiotics can influence human T cell programs and support the hypothesis that UP supplementation may preserve pro-inflammatory T cell responses during antibiotic therapy, representing a potential metabolic strategy to mitigate antibiotic-induced immunotoxicity.

PMID 42668664
Read full article →
PubMedEuropean heart journal2026-08-30

Risk prediction by new adrenomedullin (ADM) system biomarkers: are they any better than mid-regional pro-ADM (MR-proADM) in patients with ACS?

Frydland Martin Steen MS, Møller Jacob Eifer JE, Hassager Christian C

PMID 42668423
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Factor VIIIa